

# Kelly K Hunt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1991527/publications.pdf>

Version: 2024-02-01

181  
papers

8,651  
citations

50244

46  
h-index

53190

85  
g-index

190  
all docs

190  
docs citations

190  
times ranked

9025  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 918.	3.8	1,166
2	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 160-168.	0.8	349
3	Primary treatment of cystosarcoma phyllodes of the breast. <i>Cancer</i> , 2000, 89, 1502-1511.	2.0	320
4	Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients. <i>Annals of Surgery</i> , 2009, 250, 558-566.	2.1	270
5	Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. <i>Annals of Surgical Oncology</i> , 1998, 5, 620-626.	0.7	221
6	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. <i>JAMA Oncology</i> , 2015, 1, 931.	3.4	216
7	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. <i>Nature Communications</i> , 2017, 8, 15916.	5.8	214
8	Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3386-3393.	0.8	180
9	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 203.	3.4	152
10	Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. <i>JAMA Surgery</i> , 2017, 152, 665.	2.2	149
11	Selective Surgical Localization of Axillary Lymph Nodes Containing Metastases in Patients With Breast Cancer. <i>JAMA Surgery</i> , 2015, 150, 137.	2.2	148
12	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018, 267, 946-951.	2.1	147
13	Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 392-398.	0.4	126
14	Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. <i>Annals of Surgical Oncology</i> , 2016, 23, 3190-3198.	0.7	119
15	Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases. <i>Annals of Surgical Oncology</i> , 2001, 8, 425-431.	0.7	117
16	Feasibility of postmastectomy radiation therapy after TRAM flap breast reconstruction. <i>Annals of Surgical Oncology</i> , 1997, 4, 377-384.	0.7	104
17	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 508.	3.4	103
18	Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. <i>Cancer</i> , 2018, 124, 4495-4503.	2.0	100

#	ARTICLE	IF	CITATIONS
19	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 742-757.	0.4	98
20	Neoadjuvant Therapy in the Treatment of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 505-523.	0.6	97
21	A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. <i>Annals of Surgical Oncology</i> , 2016, 23, 2438-2445.	0.7	95
22	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 929.	3.4	94
23	GENE THERAPY: Hurdles and Hopes for Cancer Treatment. <i>Science</i> , 2002, 297, 415-416.	6.0	88
24	Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection. <i>Annals of Surgery</i> , 2012, 256, 428-436.	2.1	84
25	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. <i>Oncologist</i> , 2017, 22, 1292-1300.	1.9	84
26	Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 170-177.	0.5	82
27	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 293-305.	2.1	80
28	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3996-4013.	3.2	77
29	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. <i>Molecular Cancer Research</i> , 2017, 15, 45-58.	1.5	73
30	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , 2018, 24, 1434-1444.e7.	2.9	73
31	Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 673-680.	0.7	72
32	Cost and Complications of Local Therapies for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw178.	3.0	72
33	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 6594-6610.	3.2	70
34	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2018, 18, 913.	1.1	69
35	Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. <i>JAMA Network Open</i> , 2021, 4, e210945.	2.8	66
36	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2406-2418.	0.4	64

#	ARTICLE	IF	CITATIONS
37	Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?. <i>Annals of Surgical Oncology</i> , 2015, 22, 4270-4279.	0.7	62
38	Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1508-1514.	0.7	62
39	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. <i>Annals of Surgical Oncology</i> , 2017, 24, 375-397.	0.7	61
40	Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 418-424.	0.7	58
41	Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. <i>JAMA Surgery</i> , 2019, 154, 800.	2.2	58
42	Cyclin E as a prognostic and predictive marker in breast cancer. <i>Seminars in Cancer Biology</i> , 2005, 15, 319-326.	4.3	56
43	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 593-607.	1.9	54
44	Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. <i>Annals of Surgical Oncology</i> , 2017, 24, 2925-2934.	0.7	54
45	The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. , 2000, 88, 1417-1424.		51
46	Breast conservation therapy as a treatment option for the elderly. <i>Cancer</i> , 2001, 92, 1092-1100.	2.0	50
47	Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 26-33.	3.2	49
48	Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). <i>American Journal of Roentgenology</i> , 2018, 210, 669-676.	1.0	47
49	SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3510-3516.	0.7	47
50	Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells. <i>Cancer Research</i> , 2013, 73, 5556-5568.	0.4	46
51	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2991-3002.	3.2	46
52	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1385689.	2.1	46
53	Mesenchymal to epithelial transition in sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 593-601.	1.3	44
54	Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. <i>Annals of Surgical Oncology</i> , 2017, 24, 3502-3509.	0.7	44

#	ARTICLE	IF	CITATIONS
55	Utility of Breast Sentinel Lymph Node Biopsy Using Day-Before-Surgery Injection of High-Dose 99mTc-Labeled Sulfur Colloid. <i>Annals of Surgical Oncology</i> , 2001, 8, 821-827.	0.7	43
56	Role of conservation therapy for invasive lobular carcinoma of the breast. <i>Annals of Surgical Oncology</i> , 1997, 4, 650-654.	0.7	42
57	Cytoplasmic Cyclin E and Phospho-“Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. <i>American Journal of Pathology</i> , 2016, 186, 1900-1912.	1.9	42
58	Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 652-659.	0.7	41
59	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. <i>JAMA Surgery</i> , 2016, 151, 347.	2.2	40
60	Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation. <i>Cancer Research</i> , 2009, 69, 2817-2825.	0.4	39
61	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1751-1764.	1.9	39
62	Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. <i>Cancer</i> , 2018, 124, 2923-2930.	2.0	39
63	Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. <i>Cancer Research</i> , 2018, 78, 5481-5491.	0.4	39
64	Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2000, 7, 656-664.	0.7	38
65	<scp>GATA</scp>-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. <i>Histopathology</i> , 2015, 67, 245-254.	1.6	38
66	DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. <i>Journal of Cancer</i> , 2017, 8, 2653-2662.	1.2	38
67	Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2630-2638.	0.8	38
68	Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database. <i>PLoS ONE</i> , 2014, 9, e89778.	1.1	37
69	Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 11-14.	0.9	37
70	Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1119-1127.	0.8	36
71	The Landmark Series: Axillary Management in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 724-729.	0.7	36
72	LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients. <i>PLoS Genetics</i> , 2012, 8, e1002538.	1.5	35

#	ARTICLE	IF	CITATIONS
73	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 14897-14911.	0.8	35
74	Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 2385-2390.	0.7	34
75	Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. <i>Annals of Surgical Oncology</i> , 2018, 25, 2193-2200.	0.7	34
76	Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 493-502.	0.4	33
77	Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 529-538.	0.7	32
78	Local Recurrence and Survival Among Black Women With Early-Stage Breast Cancer Treated With Breast-Conservation Therapy or Mastectomy. <i>Annals of Surgical Oncology</i> , 1999, 6, 241-248.	0.7	32
79	Benefit of Adjuvant Brachytherapy Versus External Beam Radiation for Early Breast Cancer: Impact of Patient Stratification on Breast Preservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 274-284.	0.4	32
80	Feasibility of Breast Conservation Therapy in Metachronous or Synchronous Bilateral Breast Cancer. <i>Annals of Surgical Oncology</i> , 1999, 6, 102-108.	0.7	31
81	Primary Tumor Response to Induction Chemotherapy as a Predictor of Histological Status of Axillary Nodes in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 1999, 6, 762-767.	0.7	31
82	Combined Modality Management of Retroperitoneal Sarcomas: A Single-Institution Series of 121 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 158-165.	0.4	31
83	Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. <i>Cell Cycle</i> , 2016, 15, 1579-1590.	1.3	31
84	Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. <i>Journal of Surgical Oncology</i> , 2018, 117, 1188-1194.	0.8	31
85	Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems for Soft Tissue Sarcoma of the Trunk and Extremities. <i>Annals of Surgical Oncology</i> , 2018, 25, 1126-1132.	0.7	30
86	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7288-7300.	3.2	29
87	Ductal Carcinoma In Situ and Margins &#x2013;mm. <i>Annals of Surgery</i> , 2019, 269, 150-157.	2.1	29
88	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 367-379.	2.9	29
89	Tumor Suppressor Gene Smad4/DPC4, Its Downstream Target Genes, and Regulation of Cell Cycle. <i>Annals of the New York Academy of Sciences</i> , 1999, 880, 31-37.	1.8	27
90	Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer. <i>Annals of Surgical Oncology</i> , 2000, 7, 435-440.	0.7	26

#	ARTICLE	IF	CITATIONS
91	Epsteinâ€“Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. <i>Modern Pathology</i> , 2021, 34, 2154-2167.	2.9	25
92	Multidisciplinary Management of Locoregional Recurrent Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2321-2328.	0.8	25
93	Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2220-2228.	0.7	24
94	Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. <i>Journal of Surgical Oncology</i> , 2017, 116, 313-319.	0.8	24
95	Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors: A Population-Based Survey Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 882-890.	0.4	23
96	Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. <i>Breast Journal</i> , 2018, 24, 28-34.	0.4	23
97	Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. <i>Clinical Breast Cancer</i> , 2018, 18, 276-281.	1.1	21
98	Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 4277-4283.	0.7	21
99	Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System. <i>Surgical Clinics of North America</i> , 2018, 98, 687-702.	0.5	20
100	Evolution in practice patterns of axillary management following mastectomy in patients with 1â€“2 positive sentinel nodes. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 435-444.	1.1	20
101	Surgeon perception versus reality: Opioid use after breast cancer surgery. <i>Journal of Surgical Oncology</i> , 2019, 119, 909-915.	0.8	20
102	Differences in Human Leukocyte Antigen Expression Between Breast Implantâ€“Associated Anaplastic Large Cell Lymphoma Patients and the General Population. <i>Aesthetic Surgery Journal</i> , 2019, 39, 1065-1070.	0.9	19
103	Local Therapy Decisional Regret in Older Women With Breast Cancer: A Population-Based Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 383-391.	0.4	19
104	American College of Surgeons Commission on Cancer Standard for Curative-intent Pulmonary Resection. <i>Annals of Thoracic Surgery</i> , 2022, 113, 5-8.	0.7	18
105	Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. <i>Annals of Surgery Open</i> , 2020, 1, e008.	0.7	18
106	Unusual Aspects of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2573-2574.	0.8	17
107	Phase 1 adaptive doseâ€“finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with highâ€“risk extremity and trunk soft tissue sarcoma. <i>Cancer</i> , 2015, 121, 3659-3667.	2.0	17
108	American Society of Breast Surgeonsâ€™ Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. <i>Annals of Surgical Oncology</i> , 2018, 25, 2965-2974.	0.7	16



#	ARTICLE	IF	CITATIONS
109	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. <i>JAMA Oncology</i> , 2019, 5, 45.	3.4	16
110	Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. <i>Cancer</i> , 2019, 125, 365-373.	2.0	16
111	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. <i>Cancers</i> , 2021, 13, 1656.	1.7	16
112	Palbociclib plus endocrine therapy significantly enhances overall survival of <sc>HR</sc>+<sc>HER2</sc> metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. <i>International Journal of Cancer</i> , 2022, 150, 2025-2037.	2.3	16
113	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	3.4	15
114	Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Annals of Surgery</i> , 2022, 275, e245-e249.	2.1	15
115	Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801. <i>Gland Surgery</i> , 2013, 2, 120-3.	0.5	15
116	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Annals of Surgical Oncology</i> , 2022, 29, 1489-1492.	0.7	15
117	A Prospective Trial of Preoperative Chemotherapy in Resectable Breast Cancer: Predictors of Breast-Conservation Therapy Feasibility. <i>Annals of Surgical Oncology</i> , 2002, 9, 228-234.	0.7	14
118	Adherence to surgical and oncologic standards improves survival in breast cancer patients. <i>Journal of Surgical Oncology</i> , 2019, 120, 148-159.	0.8	12
119	Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. <i>Annals of Surgical Oncology</i> , 2020, 27, 730-735.	0.7	12
120	Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 390-404.	1.8	12
121	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. <i>Acta Neuropathologica</i> , 2021, 142, 565-590.	3.9	12
122	Long-Term Complications Associated With Breast-Conservation Surgery and Radiotherapy. <i>Annals of Surgical Oncology</i> , 2002, 9, 543-549.	0.7	12
123	Sarcuator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 4376-4385.	0.7	12
124	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 812-822.	2.9	11
125	Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. <i>Modern Pathology</i> , 2021, 34, 2148-2153.	2.9	11
126	Utilization and Outcomes of Breast Brachytherapy in Younger Women. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 91-101.	0.4	10



#	ARTICLE	IF	CITATIONS
127	Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2017, 97, 894-902.	0.4	9
128	Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. American Journal of Surgery, 2020, 220, 140-146.	0.9	9
129	The Controversy Regarding Margin Width in Breast Cancer: Enough is Enough. Annals of Surgical Oncology, 2014, 21, 701-703.	0.7	8
130	Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Academic Radiology, 2017, 24, 191-199.	1.3	8
131	<scp>Realâ€world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. International Journal of Cancer, 2022, 150, 2012-2024.	2.3	8
132	Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization of Non-palpable Breast Lesions. Annals of Surgical Oncology, 2022, 29, 3822-3828.	0.7	8
133	Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. Annals of Surgical Oncology, 2022, 29, 7092-7100.	0.7	8
134	Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: Implications for targeting the undissected axilla. Practical Radiation Oncology, 2014, 4, 116-122.	1.1	7
135	Identification of preoperative factors associated with outcomes following surgical management of intraabdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. Journal of Surgical Oncology, 2018, 117, 879-885.	0.8	7
136	Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Advances in Radiation Oncology, 2020, 5, 824-833.	0.6	7
137	Effect of Surgeon Factors on Long-Term Patient-Reported Outcomes After Breast-Conserving Therapy in Older Breast Cancer Survivors. Annals of Surgical Oncology, 2020, 27, 1013-1022.	0.7	7
138	Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. Journal of Surgical Oncology, 2021, 124, 989-994.	0.8	7
139	Crossover Effects of Estrogen Receptor Status on Breast Cancer-Specific Hazard Rates by Age and Race. PLoS ONE, 2014, 9, e110281.	1.1	7
140	Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3â€5.8. Annals of Surgical Oncology, 2022, , 1.	0.7	7
141	Preclinical experimental therapeutic approaches in soft tissue sarcoma. , 1999, 17, 78-82.		6
142	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. Annals of Surgical Oncology, 2020, 27, 2229-2237.	0.7	6
143	Evaluation of Sensitivity to Endocrine Therapy Index (SET <sub>2,3</sub> ) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clinical Cancer Research, 2022, 28, 3287-3295.	3.2	6
144	Special considerations in breast cancer risk and survival. , 1999, 71, 250-260.		5

#	ARTICLE	IF	CITATIONS
145	Educational Review: Role of the Surgeon in Hereditary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 368-378.	0.7	5
146	Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. <i>Aesthetic Surgery Journal</i> , 2018, 38, .	0.9	5
147	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2021, 274, e150-e159.	2.1	5
148	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020, 27, 359-366.	0.7	5
149	Inflammatory Breast Cancer at the Extremes of Age. <i>Annals of Surgical Oncology</i> , 2021, 28, 5626-5634.	0.7	5
150	Predictors of Locoregional Recurrence Among Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2002, 9, 256-265.	0.7	5
151	Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles. <i>Annals of Surgical Oncology</i> , 2020, 27, 2269-2275.	0.7	4
152	Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. <i>Annals of Surgical Oncology</i> , 2021, 28, 570-575.	0.7	4
153	Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	4
154	Sentinel lymph node dissection in early stage breast cancer. <i>Breast Cancer</i> , 2002, 9, 282-288.	1.3	3
155	Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 102-110.	0.4	3
156	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. <i>Cancers</i> , 2020, 12, 712.	1.7	3
157	MYC and NOTCH1-positive postradiation cutaneous angiosarcoma of the breast. <i>Breast Journal</i> , 2021, 27, 264-267.	0.4	3
158	Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 5477-5485.	0.7	3
159	Simultaneous inference of a misclassified outcome and competing risks failure time data. <i>Journal of Applied Statistics</i> , 2015, 42, 1080-1090.	0.6	2
160	Clinical trials—Designing, implementing, and collaborating. <i>Journal of Surgical Oncology</i> , 2020, 122, 25-28.	0.8	2
161	LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. <i>Oncogenesis</i> , 2021, 10, 40.	2.1	2
162	Primary treatment of cystosarcoma phyllodes of the breast. , 2000, 89, 1502.		2

#	ARTICLE	IF	CITATIONS
163	Organizing a breast cancer database: data management. Chinese Clinical Oncology, 2016, 5, 45-45.	0.4	2
164	ASO Author Reflections: Technical Standards for Cancer Surgery: From "How I Do It" to "How We Do It". Annals of Surgical Oncology, 2022, 29, 6559-6560.	0.7	2
165	National Cancer Database trends in surgical resection of the breast primary for stage IV breast cancer. Surgical Oncology, 2022, , 101778.	0.8	2
166	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 637-644.	0.4	1
167	Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip?. Annals of Surgical Oncology, 2016, 23, 3432-3434.	0.7	1
168	Postmastectomy Radiation Treatment Rates as a Quality Measure: An Opportunity for Compliance Through Collaboration. Annals of Surgical Oncology, 2016, 23, 2377-2379.	0.7	1
169	Imaging Surveillance After Definitive Treatment for Breast Cancer. Annals of Surgical Oncology, 2018, 25, 3790-3792.	0.7	1
170	Satisfaction and Sustainability in a Surgical Career. Annals of Surgical Oncology, 2018, 25, 2785-2789.	0.7	1
171	Challenges in Clinical Trial Implementation: Results from a Survey of the National Accreditation Program of Breast Centers (NAPBC). Annals of Surgical Oncology, 2019, 26, 4364-4371.	0.7	1
172	Management and outcomes of ruptured, perforated or fistulized tumors of mesenchymal origin. Journal of Surgical Oncology, 2020, 121, 474-479.	0.8	1
173	Reply to A. Thomsen et al. Journal of Clinical Oncology, 2020, 38, 3577-3577.	0.8	1
174	Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases. , 2001, 8, 425.		1
175	Response to Letter to the Editor: Isolated Tumor Cells in Sentinel Lymph Nodes and Clinical Implications for Early Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2661-2661.	0.7	0
176	Risky Business: Identifying Risk Factors Associated With Lymphedema After Breast Cancer. Archives of Surgery, 2010, 145, 1063.	2.3	0
177	Integrating New Knowledge and Surgical Innovation into the Diagnosis and Management of Breast Cancer. Surgical Oncology Clinics of North America, 2018, 27, xv-xvi.	0.6	0
178	ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, , 1.	0.7	0
179	Have we made progress in inflammatory breast cancer? Not so fast. Oncology, 2011, 25, 276, 278.	0.4	0
180	Abstract P2-05-02: Low molecular weight cyclin E facilitate replication stress tolerance in breast cancer development. Cancer Research, 2022, 82, P2-05-02-P2-05-02.	0.4	0

#	ARTICLE	IF	CITATIONS
181	ASO Visual Abstract: Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Annals of Surgical Oncology, 2022, , 1.	0.7	0